Press Release

VIDEO: Loebsack Sponsored Legislation to Create National, Coordinated Response to Diabetes Heads to President for Signature

f t # e
Washington, October 11, 2017 | Joe Hand (202-225-6576) | comments
Congressman Dave Loebsack released the following statement today after the House of Representatives passed S. 920, the National Clinical Care Commission Act. This legislation will help improve and coordinate a national response to diabetes, and other metabolic and autoimmune diseases, by establishing a private-public Commission charged with making recommendations to streamline federal investments, as well as improving coordination and clinical care outcomes. Loebsack and Rep. Pete Olson were the bipartisan cosponsors of the House version of this legislation, which passed by unanimous consent on a voice vote and now heads to President Trump for his signature. Video of Loebsack discussing the legislation on the House floor can be found here.

“The passage of the National Clinical Care Commission Act will help the nation undertake a more proactive and innovative approach to diabetes, for which the United States spends $322 billion annually,” said Loebsack. “The work of the Commission will help improve the lives of the tens of millions of Americans living with diabetes, while simultaneously beginning the process of reducing the staggering impact of diabetes and its complications. I am proud that this bill passed by a unanimous vote and will fight to ensure the Commission is set up expeditiously so it can begin its important work.”

The commission brings together clinical endocrinologists, specialists, health care professionals, patients and representatives from the federal agencies. Specifically, the National Clinical Care Commission will help improve care by:
•    Identifying gaps where new approaches are needed to improve diabetes care
•    Eliminating duplication and conflicting efforts and assisting in coordination across all federal agencies
•    Leveraging the significant federal investment in public health by evaluating best practices and other resources and tools for diabetes health care professionals and patients
•    Evaluating the utilization and data collection mechanisms of existing programs
•    Providing guidance on diabetes clinical care to maximize the effectiveness of our strong federal investment in diabetes research

f t # e